Form 4: Exact Sciences Director Sells Shares Post-Merger

Leslie Trigg, a director of Exact Sciences Corp., reported the disposition of all her common stock holdings following the company's merger with Abbott Laboratories' subsidiary.

Summary

• Leslie Trigg, a director of Exact Sciences Corp., reported changes in beneficial ownership via a Form 4 filing.
• On March 23, 2026, Badger Merger Sub I, Inc., a wholly-owned subsidiary of Abbott Laboratories, merged with Exact Sciences Corporation.
• Exact Sciences Corporation survived the merger as a direct, wholly-owned subsidiary of Abbott Laboratories.
• At the effective time of the merger, each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest.
• Shares of common stock subject to vesting, repurchase, or other lapse restrictions under Issuer stock plans were deemed fully vested, cancelled, and converted into the merger consideration.
• Leslie Trigg disposed of 3,244 shares of Common Stock on March 23, 2026, followed by a disposition of 13,925 shares on the same date, resulting in zero beneficially owned shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Exact Sciences shareholders, who received a definitive cash value for their shares as part of the acquisition by Abbott Laboratories. The transaction concludes Exact Sciences' journey as an independent public entity.

Positives

• Shareholders of Exact Sciences Corporation received a definitive cash consideration of $105.00 per share as part of the merger.
• Restricted stock units and other shares subject to vesting were fully vested and converted into the merger consideration, providing liquidity to holders.

Negatives

• Exact Sciences Corporation is no longer an independent publicly traded entity, having become a wholly-owned subsidiary of Abbott Laboratories.

Risks

• No specific new risks are identified in this Form 4 filing, as it primarily reports the completion of a merger and related insider stock transactions.

Future Outlook

The filing indicates that Exact Sciences Corporation has become a wholly-owned subsidiary of Abbott Laboratories, implying its future operations will be integrated within Abbott's structure. No independent forward-looking statements for Exact Sciences are provided.

Management Comments

• The merger agreement, dated November 19, 2025, stipulated that Merger Sub would merge with Exact Sciences, with Exact Sciences surviving as a wholly-owned subsidiary of Parent.
• At the effective time of the merger, each share of common stock was converted into the right to receive $105.00 in cash.
• Shares subject to vesting, repurchase, or other lapse restrictions under Issuer stock plans were fully vested, cancelled, and converted into the merger consideration.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects the final stages of a significant M&A event in the diagnostics and healthcare industry, where a larger player like Abbott Laboratories acquires a specialized company like Exact Sciences. This trend often consolidates market share and integrates complementary technologies.

Comparison to Industry Standards

• StockSavvy.ai observes that the cash consideration of $105.00 per share represents a specific valuation for Exact Sciences at the time of the merger. Without details on the premium paid or Exact Sciences' prior market valuation, a direct comparison to industry-standard acquisition multiples (e.g., EV/EBITDA, P/S) for similar diagnostics companies like Quest Diagnostics or LabCorp is not possible from this filing alone. However, such a cash-out merger is a common exit strategy for shareholders in successful growth companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $105.00 in cash per share, providing a definitive exit and liquidity for their investment.
• Employees: While not explicitly stated, employees holding restricted stock units saw them fully vested and converted into cash, which is generally positive. The long-term impact on employment structure within the combined entity is not detailed.
• Company (Exact Sciences): Ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Abbott Laboratories.

Next Steps

• No specific future actions or milestones for the now-private Exact Sciences are mentioned in this filing, as it primarily reports the insider's stock disposition post-merger.

Key Dates

Recommendation

The company's common stock has been converted into a right to receive $105.00 in cash per share as a result of the merger, meaning the stock is no longer publicly traded. Existing shareholders should ensure they receive their cash consideration, while new investors cannot purchase shares.

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Acquisition, Form 4, Insider Transaction, Stock Disposition, Cash Consideration, Corporate Action